Amyloidosis
- PMID: 7888076
- DOI: 10.3109/10408369409084679
Amyloidosis
Abstract
The biochemistry of amyloidosis as it relates to clinical medicine and experimental pathology is presented. Amyloidoses are complex disorders in which normally soluble precursors undergo pathological conformational changes and polymerize as insoluble fibrils with the beta-pleated sheet conformation. Over the past 20 years, 16 biochemically diverse proteins have been identified as fibrillar constituents of amyloid deposits; in all cases the protein-protein interactions that result in amyloid fibril formation appear to be stabilized both by the structure and the microenvironment of the precursor protein. Either genetic predisposition or dysfunctions of the immune system favor amyloid fibril formation. In particular, macrophage function is a factor in the pathogenesis of many of the amyloidoses. The diagnosis of amyloidosis involves acquisition of a tissue biopsy, staining of the specimen with Congo red, and observation of classic green birefringence on polarization microscopy. The subdiagnosis of the systemic amyloidoses involves characterization of variant or monoclonal plasma amyloid precursor proteins in the context of clinical symptoms. Treatment is generally supportive, with the use of antiinflammatory therapy, dialysis, or transplantation and genetic counseling where indicated.
Similar articles
-
The pathogenesis and biochemistry of amyloidosis.J Pathol. 1987 Jan;151(1):1-10. doi: 10.1002/path.1711510102. J Pathol. 1987. PMID: 3550020 Review.
-
[Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].Ital Heart J Suppl. 2002 Jun;3(6):590-7. Ital Heart J Suppl. 2002. PMID: 12116807 Review. Italian.
-
Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.Ann N Y Acad Sci. 2005 Dec;1066:181-221. doi: 10.1196/annals.1363.030. Ann N Y Acad Sci. 2005. PMID: 16533927 Review.
-
Pathogenesis, diagnosis and treatment of systemic amyloidosis.Philos Trans R Soc Lond B Biol Sci. 2001 Feb 28;356(1406):203-10; discussion 210-1. doi: 10.1098/rstb.2000.0766. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11260801 Free PMC article. Review.
-
[Differential diagnosis of amyloidosis].Verh Dtsch Ges Pathol. 2002;86:107-15. Verh Dtsch Ges Pathol. 2002. PMID: 12647358 Review. German.
Cited by
-
Destabilization of Ca2+-free gelsolin may not be responsible for proteolysis in Familial Amyloidosis of Finnish Type.Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2334-9. doi: 10.1073/pnas.041452598. Epub 2001 Feb 20. Proc Natl Acad Sci U S A. 2001. PMID: 11226240 Free PMC article.
-
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.Proc Natl Acad Sci U S A. 2001 May 8;98(10):5566-71. doi: 10.1073/pnas.091431798. Proc Natl Acad Sci U S A. 2001. PMID: 11344299 Free PMC article.
-
Transgenic mouse model of AA amyloidosis.Am J Pathol. 1999 Apr;154(4):1267-72. doi: 10.1016/S0002-9440(10)65378-3. Am J Pathol. 1999. PMID: 10233864 Free PMC article.
-
Uncovering the Mechanism of Aggregation of Human Transthyretin.J Biol Chem. 2015 Nov 27;290(48):28932-43. doi: 10.1074/jbc.M115.659912. Epub 2015 Oct 12. J Biol Chem. 2015. PMID: 26459562 Free PMC article.
-
An update on the amyloid hypothesis.Neurol Clin. 2007 Aug;25(3):669-82, vi. doi: 10.1016/j.ncl.2007.03.007. Neurol Clin. 2007. PMID: 17659184 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous